Chapter 15. Analgesics, sedatives, and neuromuscular blockade

I. RECOMMENDATIONS

Strength of Recommendations: Weak.
Quality of Evidence: Low, from poor-quality class III studies.

A. Level I

There are insufficient data to support a level I recommendation for this topic.

B. Level II

There are insufficient data to support a level II recommendation for this topic.

C. Level III*

Etomidate may be considered to control severe intracranial hypertension; however, the risks resulting from adrenal suppression must be considered.

Thiopental may be considered to control intracranial hypertension.

*In the absence of outcome data, the specific indications, choice and dosing of analgesics, sedatives, and neuromuscular-blocking agents used in the management of infants and children with severe traumatic brain injury (TBI) should be left to the treating physician.

*As stated by the Food and Drug Administration, continuous infusion of propofol for either sedation or the management of refractory intracranial hypertension in infants and children with severe TBI is not recommended.

II. EVIDENCE TABLE (see Table 1)

III. OVERVIEW

Analgesics, sedatives, and neuromuscular-blocking agents are commonly used in the management of severe pediatric TBI. Use of these agents can be divided into two major categories: 1) for emergency intubation; and 2) for management including control of elevated intracranial pressure (ICP) in the intensive care unit (ICU). This chapter evaluates these agents during ICU treatment.

Analgesics and sedatives are believed to favorably treat a number of important pathophysiological derangements in severe TBI. They can facilitate necessary general aspects of patient care such as the ability to maintain the airway, vascular catheters, and other monitors. They can also facilitate patient transport for diagnostic procedures and mechanical ventilatory support. Other proposed benefits of sedatives after severe TBI include anticonvulsant and antiemetic actions, the prevention of shivering, and attenuating the long-term psychological trauma of pain and stress. Analgesics and sedatives also are believed to be useful by mitigating aspects of secondary damage. Pain and stress markedly increase cerebral metabolic demands and can pathologically increases cerebral blood volume and raise ICP. Studies in experimental models showed that a two- to threefold increase in cerebral metabolic rate for oxygen accompanies painful stimuli (1, 2). Noxious stimuli such as suctioning can also increase ICP (3–6). Painful and noxious stimuli and stress can also contribute to increases in sympathetic tone with hypertension and bleeding from operative sites (7). However, analgesic or sedative-induced reductions in arterial blood pressure can lead to cerebral ischemia as well as vasodilation and can exacerbate increases in cerebral blood volume and ICP. In the absence of advanced neuromonitoring, care must be taken to avoid this complication.

The ideal sedative for patients with severe TBI has been described as one that is rapid in onset and offset, easily titrated to effect, has well-defined metabolism (preferably independent of end-organ function), neither accumulates nor has active metabolites, exhibits anticonvulsant actions, has no adverse cardiovascular or immune actions, and lacks drug–drug interactions while preserving the neurologic examination (8).

Neuromuscular-blocking agents have been suggested to reduce ICP by a variety of mechanisms including a reduction in airway and intrathoracic pressure with facilitation of cerebral venous outflow and by prevention of shivering, posturing, or breathing against the ventilator (9). Reduction in metabolic demands by elimination of skeletal muscle contraction has also been suggested to represent a benefit. Risks of neuromuscular blockade include the potential devastating effect of hypoxemia secondary to inadvertent extubation, risks of masking seizures, increased incidence of nosocomial seizures, increased incidence of nosocomial pneumonia (shown in adults with severe TBI) (9), cardiovascular side effects, immobility and side effects of corticosteroids. Incidence of this complication varies between 1% and over 30% of cases (5, 11, 12). Monitoring of the depth of neuromuscular blockade can shorten duration of its use in the ICU (13).

IV. PROCESS

For this update, MEDLINE was searched from 1996 through 2010 (Appendix B for search strategy), and results were supplemented with literature recommended by peers or identified from reference lists. Of 46 potentially relevant studies, two were included as evidence for this topic.

V. SCIENTIFIC FOUNDATION

The recommendations on the use of analgesics, sedatives, and neuromuscular-blocking agents in this chapter are for patients with a secure airway who are receiving mechanical ventilatory support yielding the desired arterial blood gas values and who have stable systemic hemodynamics and intravascular volume status.

Two class III studies of the use of analgesics or sedatives met inclusion criteria for this topic and provide evidence to support the recommendations: one study about etomidate and one about thiopental. These studies only addressed ICP as the outcome (14, 15). No study addressed the most commonly used analgesics and sedatives (narcotics and benzodiazepines).

Etomidate

A study by Bramwell et al (14) carried out a prospective unblinded class III study of the effect of a single dose of
etomidate (0.3 mg/kg, intravenously) on ICP >20 mm Hg in eight children with severe TBI. Etomidate reduced ICP vs. baseline in each 5-min interval during the 30-min study period. The patients in this study had severe intracranial hypertension and etomidate reduced ICP from 32.8 ± 6.6 mm Hg to 21.2 ± 5.2 mm Hg. An increase in cerebral perfusion pressure was also seen that was significant for the initial 25 mins after etomidate administration. Every patient in the study exhibited a reduction in ICP with treatment. No data were presented on cortisol levels in these patients. However, in the discussion section of the manuscript, the authors indicated that at 6 hrs after etomidate administration, adrenocorticotropic hormone stimulation tests were performed on each patient; four of the eight showed adrenal suppression. It is unclear if this degree of adrenal suppression is different from that normally observed in pediatric TBI (16). No patient showed clinical signs of adrenal insufficiency such as electrolyte disturbances or blood pressure lability, and no patient received steroid therapy.

The availability of other sedatives and analgesics that do not suppress adrenal function, small sample size and single-dose administration in the study discussed previously, and limited safety profile in pediatric TBI limit the ability to endorse the general use of etomidate as a sedative other than as an option for single-dose administration in the setting of raised ICP.

**Barbiturates**

Barbiturates can be given as a sedative at doses lower than those required to induce or maintain barbiturate coma. No report specifically addressed their use in that capacity in pediatric TBI. One report did, however, address the effects of barbiturate administration outside of the setting of refractory raised ICP. A study by de Bray et al (15) was a prospective study of the effect of a single dose of thiopental (5 mg/kg, intravenously) on middle cerebral artery flow velocity in ten children with severe TBI and compared the findings with those seen with thiopental administration in ten children under general anesthesia for orthopedic procedures. In this small study, effects on ICP were assessed in only six of the ten children with severe TBI. In those six, thiopental reduced ICP by 48%. Flow velocity was reduced by approximately 15% to 21% in the pediatric patients with TBI. Baseline ICP was 16.5 mm Hg. Cerebral perfusion pressure was not significantly changed. At the class III level, this study supports the ability of thiopental, administered as a single dose, to reduce ICP, even when only moderately increased. The effects on flow velocity are also consistent with the reduction in cerebral blood volume that would be expected to mediate the reduction in ICP produced by thiopental. No study was identified, however, that specifically addressed barbiturate use as a sedative on any other outcome parameter.

**VI. INFORMATION FROM OTHER SOURCES**

**A. Indications From the Adult Guidelines**

In the most recent adult guidelines, a chapter on “Anesthetics, Analgesics, and Sedatives” identified a class II study to recommend continuous infusion of propofol as the agent of choice.

Only case reports or mixed adult and pediatric case series have been published supporting propofol use in pediatric TBI.

---

**Table 1. Evidence table**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study Description</th>
<th>Data Class, Quality, and Reasons</th>
<th>Results and Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>de Bray et al, 1993 (15)</td>
<td>Design: prospective case series N = 10</td>
<td>Class III</td>
<td>Etomidate administration resulted in a decrease in ICP vs. baseline (p &lt; .05) without change in mean arterial pressure, thereby increasing cerebral perfusion pressure at each 5-min interval; at 6 hrs after etomidate administration, adrenocorticotropic hormone stimulation tests showed adrenal suppression in 4 of the 8 patients; however, no patient required treatment with steroids. Thiopental reduced mean ICP, measured in 6 of the 10 patients with TBI, by 48% (p &lt; .01), with no significant correlation with middle cerebral artery flow velocity; thiopental also reduced middle cerebral artery flow velocity (systolic velocities −15% ± 6.9%, p &lt; .01) and diastolic velocities (−21% ± 6.5%, p &lt; .01) in cases, not controls; reduction in middle cerebral artery flow velocity occurred in 90% cases compared with 10% controls; mean ICP, measured in 6 of the 10 patients with TBI, was reduced by 48% (p &lt; .01) with no significant correlation with middle cerebral artery flow velocity.</td>
</tr>
<tr>
<td>Bramwell et al, 2006 (14)</td>
<td>Design: prospective case series N = 10</td>
<td>Class III</td>
<td>Thiopental reduced mean ICP, measured in 6 of the 10 patients with TBI, by 48% (p &lt; .01), with no significant correlation with middle cerebral artery flow velocity; thiopental also reduced middle cerebral artery flow velocity (systolic velocities −15% ± 6.9%, p &lt; .01) and diastolic velocities (−21% ± 6.5%, p &lt; .01) in cases, not controls; reduction in middle cerebral artery flow velocity occurred in 90% cases compared with 10% controls; mean ICP, measured in 6 of the 10 patients with TBI, was reduced by 48% (p &lt; .01) with no significant correlation with middle cerebral artery flow velocity.</td>
</tr>
</tbody>
</table>

IV, intravenous; ICP, intracranial pressure; TBI, traumatic brain injury.
vere intracranial hypertension with an overall mean ICP of 25.8 mm Hg. The study did not meet inclusion criteria for these guidelines for two reasons. First, it fell just below the cutoff of 85% of TBI cases, and second, Glasgow Coma Scale score was not provided—although it is likely that the children had severe TBI given the ICP data.

Regarding the use of etomidate in critical care, including severe TBI and multiple trauma victims (28–31), there are general concerns over adrenal suppression. As stated earlier, the availability of other sedatives and analgesics that do not suppress adrenal function, along with the small sample size and single-dose administration in the single study in the evidence table (Table 1) and limited safety profile in pediatric TBI, limit the ability to endorse the general use of etomidate as a sedative other than as an option for single-dose administration in the setting of raised ICP.

VII. SUMMARY

Two studies were identified that met inclusion criteria, rendering reserved class III recommendations that 1) etomidate may be considered to decrease intracranial hypertension, although the risks resulting from adrenal suppression must be considered; and 2) thiopental, given as a single dose, may be considered to control intracranial hypertension.

Despite the common use of analgesics and sedatives in TBI management, there have been few studies of these drugs focused on pediatric patients with severe TBI, and studies meeting inclusion criteria for the most commonly used agents were lacking. Similarly, no studies were identified meeting inclusion criteria that addressed the use of neuromuscular blockade in pediatric patients with severe TBI. Until experimental comparisons among these agents are carried out, the choice and dosing of analgesics, sedatives, and neuromuscular-blocking agents used should be left to the treating physician. Based on recommendations of the Food and Drug Administration, continuous infusion of propofol is not recommended in the treatment of pediatric TBI.

VIII. KEY ISSUES FOR FUTURE INVESTIGATION

• Studies are needed comparing the various sedatives and analgesics in pediatric patients with severe TBI, examining sedative and analgesic efficacy effects on ICP, other surrogate markers, and functional outcome.
• Studies are needed to assess the toxicities, including hypotension, adrenal suppression, effects on long-term cognitive outcomes, and other adverse effects.
• Studies are needed on dosing, duration, and interaction effects with other concurrent therapies.
• Optimal sedation after severe TBI may differ between infants and older children and requires investigation. Specifically, given concerns over the effects of various anesthetics and sedatives on neuronal death in the developing brain (32, 33), studies of various analgesic and sedative regimens in infants with TBI are needed, including infants who are victims of abusive head trauma.
• The specific role of neuromuscular-blocking agents in infants and children with severe TBI needs to be defined.

REFERENCES

10. Durbin CG Jr: Neuromuscular blocking...


